Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for
primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done …

Introduction: The growing interest on how peri-‑operative interventions, especially regional
anesthesia, during cancer surgery can alter oncological outcome increasing disease free …

Global cancer burden is on the rise and many more patients present for surgery or other
oncological diagnostic or therapeutic interventions requiring anaesthesia. Oncology therapy …

Objectives Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy
(HIPEC) is associated with increased morbidity and mortality. We retrospectively analysed …

Abstract Background Surgical site infections (SSIs) are a common cause of morbidity after
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for …

Cytoreductive surgery is a surgical treatment approach that has been applied over the last 3
decades in patients with peritoneal metastases originating from intraabdominal organs. Goal …

Objectives Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS-
HIPEC) for peritoneal malignancies are complex surgeries marked with hemodynamic …

Introduction Cytoreductive surgery combined with hyperthermic intraperitoneal
chemotherapy (CRS/HIPEC) is a well-established treatment for peritoneal cancer (PC) …

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) have benefits for survival in some cancers with peritoneal metastasis. Hematologic …

Peritoneal carcinomatosis (PC) is divided into primary and secondary peritoneal
involvement. Primary PC is termed malignant peritoneal mesothelioma (MPM), which …